Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 13, 2004

View Archived Issues

TT-232, a somatostatin analogue, demonstrates in vivo antitumor activity

Novel DNA intercalating agent for antitumor therapy described

Allergan plans IND filing for Peplin's topical drug for actinic keratosis

Nanogen to acquire SYN X Pharma

Lundbeck and Merck & Co. to develop and commercialize gaboxadol

Chiesi and 3M to develop Modulite HFA products for North America

MediGene completes enrollment in final phase III trial of Polyphenon E

Eisai reports on progress of global clinical development

Maxim reviews first quarter developments

Praecis achieves primary goal for 2003

Efficacy and safety of efalizumab in the treatment of psoriasis

Improved epithelial chloride transport found with Moli-1901 in cystic fibrosis

Pregabalin reported effective and safe as adjunctive therapy for patients with partial seizures

Hyperleptinemia in lean ZDF rats reduces weight and converts white adipocytes into fat burning cells

Poseidon claims new BK(Ca) channel modulators for respiratory and cardiovascular disorders

New factor Xa/factor VIIa inhibitors covered by Merck KGaA patent

Novel caspase inhibitors discovered by Vertex researchers

New NPY Y5 antagonists and their use reported by Banyu

Pharmacia team prepares and tests new MMP inhibitors

Aventis describes adenosine A1 agonists with potential as antidiabetic agents

New beta3-adrenoceptor agonists and their use in urinary incontinence

Myfortic completes European mutual recognition procedure

Riomet launched in U.S.

New phase II trial studies effects of ALT-711 on endothelial function

Improvement in cognitive function in schizophrenics after switch to ziprasidone

Aeroneb Go Nebulizer available in U.S.

Orphan drug status for Altastaph

IND filing for phase I/II AVENGE trial of EW-A-401

Fast track status for Fibrillex

Third of four phase II trials initiated for PI-88

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...